Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study

Lung Cancer

Volumn 39, Issue 1, 2003, Pages 71-76

  Mavroudis, D ^a   Pavlakou, G ^b   Blazoyiannakis, G ^b   Veslemes, M ^c   Apostolopoulou, F ^d   Kouroussis, Ch ^a   Kakolyris, S ^a   Agelaki, S ^a   Androulakis, N ^a   Vardakis, N ^a   Magkanas, E ^a   Samonis, G ^a   Georgoulias, V ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d SISMANOGLIO HOSPITAL   (Greece)

Author keywords

Cisplatin; Etoposide; SCLC; Sequential; Topotecan

Indexed keywords

CISPLATIN; ETOPOSIDE; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; CARCINOMA, SMALL CELL; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TIME FACTORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0347928789     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00307-0     Document Type: Article

References (20)

1. Aisner J. Extensive disease small cell lung cancer: the thrill of victory; the agony of defeat. J. Clin. Oncol. 14:1996;658-665.
2. Bunn P., Carney D. Overview of chemotherapy for small cell lung cancer. Semin. Oncol. 24:(2 Suppl 7):1997;69-74.
3. Ihde D.C., Glatstein E.J., Pass H.I. Small-cell lung cancer. De Vita V.T. Jr., Hellman S., Rosemberg S.A. Cancer: principles and practice of oncology. 5th ed:1997;911-950 Lippincott-Raven, Philadelphia, PA.
4. Hsiang Y.-H., Liu L.F. Identification of mammalian DNA topoisomerase I as a intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1988;1722-1726.
5. Creemers G.J., Lund B., Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev. 20:1994;73-96.
6. Schiller J.H., Kim K., Hutson P., et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lungs: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 14:1996;2345-2352.
7. Ardizzoni A., Hansen H., Dombernowsky P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J. Clin. Oncol. 15:1997;2090-2096.
8. von Pawel J., Schiller J.H., Shepherd F., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. 17:1999;658-667.
9. Saltz L., Sirott M., Young C., et al. Phase I and pharmacologic study of topotecan given daily for 5 days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor (G-CSF). J. Natl. Cancer Inst. 85:1993;1499-1507.
10. Raymond E., Burris H.A., Rowinsky E.K., et al. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann. Oncol. 8:1997;1003-1008.
11. Lilenbaum R.C., Ratain M.J., Miller A.A., et al. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J. Clin. Oncol. 13:1995;2230-2237.
12. Miller A.B., Hoogstraten B.B., Staquet M., et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
13. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1959;457-481.
14. Kaufmann S.H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 51:1991;1129-1136.
15. Bertrand R., O'Connor P.M., Kerrigan D., et al. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer. 28A:1992;743-748.
16. Perez-Soler R., Glisson B.S., Lee J.S., et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J. Clin. Oncol. 14:1996;2785-2790.
17. Schiller J.H., Adak S., Cella D., et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 19:2001;2114-2122.
18. Kim R., Hirabayashi N., Nishiyama M., et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer. 50:1992;760-766.
19. Bonner J.A., Kozelsky T.F. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother. Pharmacol. 39:1996;109-112.
20. Jonsson E., Fridborg H., Nygren P., et al. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur. J. Clin. Pharmacol. 54:1998;509-514.